Publication Title
British journal of haematology
Document Type
Article
Publication Date
2-1-2017
Keywords
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Exanthema; Female; Fenretinide; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab
Abstract
Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma (B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a phase I-II study of fenretinide with rituximab for B-NHLs. Eligible diagnoses included indolent B-NHL or mantle cell lymphoma. The phase I design de-escalated from fenretinide at 900 mg/m
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
